Wells Fargo & Company/Mn
—- Market cap
- $272.07B
- Debt
- +$193.04B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 58% equity / 42% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: WFC stock price vs CPRX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CPRX's multiple
Needs CPRX P/E.
Implied fair value · at WFC's multiple
Needs WFC P/E.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: WFC FY 2025 (ended Dec 31, 2025) · CPRX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 58% equity / 42% debt
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WELLS FARGO & COMPANY/MN · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
CATALYST PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.07x
0.15x
Net debt / EBITDA
Leverage against operating earnings
—
-1.75x
Cash and equivalents
Liquid reserves on the balance sheet
—
$709.17M
Total debt
Interest-bearing obligations outstanding
$193.04B
$145.25M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JPMorgan Chase & Co.
WFC vs JPM
Bank of America Corporation
WFC vs BAC
Citigroup Inc.
WFC vs C
The Goldman Sachs Group, Inc.
WFC vs GS
Morgan Stanley
WFC vs MS
Capital One Financial Corporation
WFC vs COF
TRUIST FINANCIAL CORP
WFC vs TFC
Jazz Pharmaceuticals plc
WFC vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
WFC vs SUPN
PERRIGO Co plc
WFC vs PRGO
Harmony Biosciences Holdings, Inc.
WFC vs HRMY
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.